摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

吉美前列素 | 64318-79-2

中文名称
吉美前列素
中文别名
——
英文名称
gemeprost
英文别名
16,16-dimethyl-trans-Δ2-PGE1 methyl ester;Cervagem;methyl (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate
吉美前列素化学式
CAS
64318-79-2
化学式
C23H38O5
mdl
——
分子量
394.552
InChiKey
KYBOHGVERHWSSV-VNIVIJDLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    438.73°C (rough estimate)
  • 密度:
    1.0380 (rough estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    28
  • 可旋转键数:
    13
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.74
  • 拓扑面积:
    83.8
  • 氢给体数:
    2
  • 氢受体数:
    5

ADMET

代谢
静脉给药后,吉美前列腺素通过解迅速代谢为自由酸,半衰期为10-15分钟。随后,自由酸通过β-和ω-氧化被灭活。
After intravenous administration, gemeprost is rapidly metabolized via hydrolysis to the free acid with half life of 10-15 minutes. The free acid is then inactivated by β- and ω-oxidation.
来源:DrugBank
吸收、分配和排泄
  • 吸收
gemeprost的系统性吸收有限,大约有12-28%的给药剂量达到系统性循环。阴道给药后,血浆浓度在2-3小时内达到峰值。
Systemic absorption of gemeprost is limited with about 12-28% of administered dose of gemeprost reaching the systemic circulation. Following vaginal administration, peak plasma concentration is reached after 2-3 hours.
来源:DrugBank
吸收、分配和排泄
  • 消除途径
在大约24小时内有大约50%的剂量以代谢物形式通过尿液排出。
About 50% of the dose eliminated as metabolites in the urine during the first 24 hours.
来源:DrugBank

安全信息

  • 危险等级:
    6.1(b)
  • 危险品运输编号:
    UN 3249
  • 包装等级:
    III
  • 危险类别:
    6.1(b)
  • 储存条件:
    库房应保持低温、通风和干燥。

SDS

SDS:2ba0d8dec413d2c8300702aa1c01860b
查看

制备方法与用途

用法用量
  • 软化和扩张子宫颈:术前3小时将1枚栓剂(1mg)插入阴道后穹窿,维持12小时。
  • 终止妊娠:每3~6小时给药一次,每次使用1枚栓剂(1mg),即阴道后穹窿给药。通常在首次或第二次用药后开始出现阴道出血及子宫收缩。治疗应继续到给予第5枚栓剂为止,除非完全流产提前发生。如果5枚栓剂均未见效,则需于24小时后再进行一个疗程。
作用与用途

吉美前列素是一种合成的PGE1生物,较为稳定且选择性较高,不良反应较少。它能强烈收缩子宫平滑肌,对消化道平滑肌和血压影响较小,并具有软化和扩张宫颈管的作用。其效力比PGF2α更强,未怀孕子宫对于该药物的敏感度远大于早孕期子宫。妊娠继续时,子宫对于药物的敏感性增加。本品子宫内给药效果最佳,注射或阴道内使用也同样有效。

类别
  • 类别:有毒物质
  • 毒性分级:高毒
  • 急性毒性
    • 口服-大鼠 LD50: 56.5 毫克/公斤
    • 口服-小鼠 LD50: 59 毫克/公斤
危险特性
  • 热分解、辛辣刺激烟雾
储运特性

库房需低温通风干燥保存。

灭火剂

反应信息

  • 作为反应物:
    描述:
    吉美前列素 生成 (E)-7-[(1R,2R,3R)-3-Hydroxy-2-((E)-(R)-3-hydroxy-4,4-dimethyl-oct-1-enyl)-5-oxo-cyclopentyl]-hept-2-enoic acid
    参考文献:
    名称:
    XAYASI, MASAKI;KORI, SEHJDZI;VAKATSUKA, XIROXISA
    摘要:
    DOI:
  • 作为产物:
    描述:
    methyl (E)-7-[(1R,2R,3R)-2-[(E,3R)-4,4-dimethyl-3-(oxan-2-yloxy)oct-1-enyl]-3-(oxan-2-yloxy)-5-oxocyclopentyl]hept-2-enoate 生成 吉美前列素
    参考文献:
    名称:
    XAYASI, MASAKI;KORI, SEHJDZI;VAKATSUKA, XIROXISA
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES DE SITE DE LIAISON MODIFIÉES ET USAGE CORRESPONDANT
    申请人:SMARTCELLS INC
    公开号:WO2010088261A1
    公开(公告)日:2010-08-05
    In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.
    在一个方面,该公开提供了包括多价凝集素的交联材料,其中该多价凝集素具有至少两个葡萄糖结合位点,其中该凝集素包括至少一个与亲和配体共价连接的亲和配体,该亲和配体能够与至少一个所述结合位点中的葡萄糖竞争结合;以及包括绑定到共轭框架的两个或更多个独立亲和配体的共轭物,其中这两个或更多个亲和配体葡萄糖在所述结合位点上与凝集素竞争结合,其中由于不同共轭物上的凝集素和亲和配体之间的非共价相互作用,共轭物在材料内交联。这些材料旨在根据所需葡萄糖浓度释放共轭物的量。根据最终应用,在各种实施例中,共轭物还可以包括药物和/或可检测标记。
  • N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
    申请人:——
    公开号:US20030105132A1
    公开(公告)日:2003-06-05
    The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R 1 is optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C 1-6 alkoxy, —NR 2 R 3 or —NR 4 SO 2 R 5 ; X is the linkage —(CH 2 ) n — or —(CH 2 ) q —O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C 1-4 alkoxy; hydroxy; hydroxy(C 1-3 alkyl); C 3-7 cycloalkyl; carbocyclyl; heterocyclyl; or by C 1-4 alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R 8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5 - or 6 -membered carbocyclic or heterocyclyic ring. 1
    该发明涉及用于治疗性功能障碍的化合物(I)的公式,其中R1是可选择取代的C1-6烷基,可选择取代的碳环烷基,可选择取代的杂环烷基,氢,C1-6烷氧基,—NR2R3或—NR4SO2R5;X是连接基—(CH2)n—或—( )q—O—(其中Y连接到氧原子);其中连接基X中的一个或多个氢原子可以独立地被C1-4烷氧基,羟基,羟基(C1-3烷基),C3-7环烷基,碳环烷基,杂环烷基或可选择取代的一个或多个或苯基的C1-4烷基替代;n为3、4、5、6或7;q为2、3、4、5或6;Y为苯基或吡啶基,每个基都可以被取代;或相邻碳原子上的两个R8基连同相互连接的碳原子可以形成一个可选择取代的5-或6-成员碳环或杂环环。
  • New indazole and indolone derivatives and their use pharmaceuticals
    申请人:Allerton Norfor Charlotte Moira
    公开号:US20050267096A1
    公开(公告)日:2005-12-01
    The present invention provides for compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.
    本发明提供了一类多巴胺激动剂的化合物,具体来说是一类选择性作用于D3而非D2的激动剂。这些化合物可用于治疗和/或预防性功能障碍,例如女性性功能障碍(FSD),特别是女性性唤醒障碍(FSAD),性欲不振障碍(HSDD;对性欲缺乏兴趣),女性性高潮障碍(FOD;无法达到高潮);以及男性性功能障碍,特别是男性勃起功能障碍(MED)。本文提到的男性性功能障碍包括射精障碍,如早泄,无法达到高潮的无性感(无法达到高潮)或性欲障碍,如性欲不振(HSDD;对性欲缺乏兴趣)。这些化合物还可用于治疗神经精神障碍和神经退行性疾病。
  • [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2012143144A1
    公开(公告)日:2012-10-26
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮酸重复的激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体的化合物的新颖化合物(I)的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
  • [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
    申请人:ORIGENIS GMBH
    公开号:WO2012143143A1
    公开(公告)日:2012-10-26
    The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.
    本发明涉及一种能够抑制一个或多个激酶,特别是SYK(脾酪氨酸激酶)、LRRK2(富含亮酸重复激酶2)和/或MYLK(肌球蛋白轻链激酶)或其突变体的化合物的新颖化合物(I)的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
查看更多